ブレイブハート・バイオ
BRVE
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q3 | -0.51 | $0 | -$24M |
| 2026 Q2 | -0.30 | $0 | -$17M |
| 2026 Q1 | -2.08 | $0 | -$5M |
| 2025 Q4 | 0.00 | $0 | -$2M |